In vitro and in vivo effects of penicillin and clindamycin on expression of group A beta-hemolytic streptococcal capsule.
Encapsulation of group A beta-hemolytic streptococci (GABHS) is an important virulence factor. The changes that occur in the frequency of encapsulation of GABHS during pharyngotonsillitis, in 20 patients treated with penicillin and 20 treated with clindamycin, were investigated. The effects of subinhibitory concentrations of these agents were also evaluated in vitro. At day 4, 8 of 10 (80%) GABHS isolates recovered from children treated with penicillin were encapsulated, compared with 1 of 5 (20%) of those from children treated with clindamycin (P < 0.05). Two days following 10 days of therapy, GABHS was eliminated from 13 of the 20 (65%) children treated with penicillin and from all treated with clindamycin (P < 0.05). At that time, six of the seven GABHS isolates recovered in patients treated with penicillin were encapsulated. GABHS were not detected after 4 days of therapy in those treated with clindamycin. Incubation of GABHS isolates with one-half of the MIC of clindamycin reduced the frequency of encapsulation, compared with that after incubation with one-half of the MIC of penicillin (12.5 versus 67.5%). These data illustrate the superiority of clindamycin over penicillin in reducing the expression of a capsule by GABHS.
D016667:Bacterial Capsules / Q000096:biosynthesis* / Q000187:drug effects*; D001426:Bacterial Proteins / Q000096:biosynthesis; D002648:Child; D002981:Clindamycin / Q000494:pharmacology*; D006801:Humans; D008826:Microbial Sensitivity Tests; D010406:Penicillins / Q000494:pharmacology*; D010612:Pharyngitis / Q000188:drug therapy / Q000382:microbiology; D013290:Streptococcal Infections; D013297:Streptococcus pyogenes / Q000187:drug effects* / Q000378:metabolism*; D014069:Tonsillitis / Q000188:drug therapy / Q000382:microbiology; D001618:beta-Lactamases / Q000096:biosynthesis
D001426:Bacterial Proteins; D010406:Penicillins; D002981:Clindamycin; D001618:beta-Lactamases